Systematic literature review and meta-analysis of the efficacy and safety of prescription opioids, including abuse-deterrent formulations, in non-cancer pain management

Pain Medicine (United States)

Volumn 15, Issue 1, 2014, Pages 79-92

  Michna, Edward ^a   Cheng, Wendy Y ^b   Korves, Caroline ^b   Birnbaum, Howard ^b   Andrews, Ryan ^b   Zhou, Zhou ^b   Joshi, Ashish V ^c   Schaaf, David ^c   Mardekian, Jack ^c   Sheng, Mei ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b ANALYSIS GROUP   (United States)

^c PFIZER INC   (United States)

Author keywords

Opioids; Pain management; Safety

Indexed keywords

CODEINE; FENTANYL; HYDROCODONE; HYDROMORPHONE; METHADONE; MORPHINE; MORPHINE SULFATE; NALTREXONE; OPIATE; OXYCODONE; OXYMORPHONE; PLACEBO; TRAMADOL;

CANCER PAIN; CLINICAL TRIAL; CONSTIPATION; DIZZINESS; DROWSINESS; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; HEADACHE; HUMAN; META ANALYSIS; PAIN; PRURITUS; REVIEW; SOMNOLENCE; SYSTEMATIC REVIEW; VERTIGO; VOMITING;

OPIOIDS; PAIN MANAGEMENT; SAFETY;

ADULT; CHEMISTRY, PHARMACEUTICAL; CLINICAL TRIALS AS TOPIC; CONSTIPATION; DELAYED-ACTION PREPARATIONS; HEADACHE DISORDERS, SECONDARY; HUMANS; NARCOTICS; NAUSEA; OPIOID-RELATED DISORDERS; PAIN MANAGEMENT; PAIN, POSTOPERATIVE; SUBSTANCE-RELATED DISORDERS; TREATMENT OUTCOME;

EID: 84892512959     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/pme.12233     Document Type: Review

References (82)

1. American Pain Society. Pain assessment and treatment in the managed care environment. A position statement from the American Pain Society. Case Manager 2000;11(5):50-53.
2. Committee on Advancing Pain Research C, Education, Medicine Io. Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research. Washington, DC: The National Academies Press; 2011.
3. Brennan F, Carr DB, Cousins M. Pain management: A fundamental human right. Anesth Analg 2007;105(1):205-221.
4. Administration SAaMHS. Results from the 2008 National Survey on Drug Use and Health: National Findings. Office of Applied Studies NSH-, DHHS Publication No. SMA 09-4434, editor. Rockville, MD 2009.
5. Passik SD. Issues in long-term opioid therapy: Unmet needs, risks, and solutions. Mayo Clin Proc 2009;84(7):593-601.
6. Katz N, Fernandez K, Chang A, Benoit C, Butler SF. Internet-based survey of nonmedical prescription opioid use in the United States. Clin J Pain 2008;24(6):528-535.
7. Korff MV, Saunders K, Thomas Ray G, etal. De facto long-term opioid therapy for noncancer pain. Clin J Pain 2008;24(6):521-527.
8. Papaleontiou M, Henderson CR Jr, Turner BJ, etal. Outcomes associated with opioid use in the treatment of chronic noncancer pain in older adults: A systematic review and meta-analysis. J Am Geriatr Soc 2010;58(7):1353-1369.
9. Higgins JPT, Green S. Special topics in statistics. In: Higgins JPT, Deeks JJ, Altman DG, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration; 2011. Available at: www.cochrane-handbook.org (accessed September 2013).
10. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7(3):177-188.
11. Wells GA, Sultan SA, Chen L, Khan M, Coyle D. Indirect treatment comparison [computer program], 1.0 edition. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2009.
12. Katz N, Rauck R, Ahdieh H, etal. A 12-week, randomized, placebo-controlled trial assessing the safety and efficacy of oxymorphone extended release for opioid-naive patients with chronic low back pain. Curr Med Res Opin 2007;23(1):117-128.
13. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50(4):1088-1101.
14. StataCorp. Stata Statistical Software: Release 11. College Station, TX: StataCorp LP; 2009.
15. Buynak R, Shapiro DY, Okamoto A, etal. Efficacy and safety of tapentadol extended release for the management of chronic low back pain: Results of a prospective, randomized, double-blind, placebo- and active-controlled phase III study. Expert Opin Pharmacother 2010;11(11):1787-1804.
16. Caldwell JR, Rapoport RJ, Davis JC, etal. Efficacy and safety of a once-daily morphine formulation in chronic, moderate-to-severe osteoarthritis pain: Results from a randomized, placebo-controlled, double-blind trial and an open-label extension trial. J Pain Symptom Manage 2002;23(4):278-291.
17. Gana TJ, Pascual ML, Fleming RR, etal. Extended-release tramadol in the treatment of osteoarthritis: A multicenter, randomized, double-blind, placebo-controlled clinical trial. Curr Med Res Opin 2006;22(7):1391-1401.
18. Hale ME, Ahdieh H, Ma T, Rauck R. Efficacy and safety of OPANA ER (oxymorphone extended release) for relief of moderate to severe chronic low back pain in opioid-experienced patients: A 12-week, randomized, double-blind, placebo-controlled study. J Pain 2007;8(2):175-184.
19. Kivitz A, Ma C, Ahdieh H, Galer BS. A 2-week, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase III trial comparing the efficacy of oxymorphone extended release and placebo in adults with pain associated with osteoarthritis of the hip or knee. Clin Ther 2006;28(3):352-364.
20. Markenson JA, Croft J, Zhang PG, Richards P. Treatment of persistent pain associated with osteoarthritis with controlled-release oxycodone tablets in a randomized controlled clinical trial. Clin J Pain 2005;21(6):524-535.
21. Matsumoto AK, Babul N, Ahdieh H. Oxymorphone extended-release tablets relieve moderate to severe pain and improve physical function in osteoarthritis: Results of a randomized, double-blind, placebo- and active-controlled phase III trial. Pain Med 2005;6(5):357-366.
22. Vorsanger G, Xiang J, Jordan D, Farrell J. Post hoc analysis of a randomized, double-blind, placebo-controlled efficacy and tolerability study of tramadol extended release for the treatment of osteoarthritis pain in geriatric patients. Clin Ther 2007;29(suppl):2520-2535.
23. Vorsanger GJ, Xiang J, Gana TJ, Pascual ML, Fleming RR. Extended-release tramadol (tramadol ER) in the treatment of chronic low back pain. J Opioid Manag 2008;4(2):87-97.
24. Aqua K, Gimbel JS, Singla N, etal. Efficacy and tolerability of oxymorphone immediate release for acute postoperative pain after abdominal surgery: A randomized, double-blind, active- and placebo-controlled, parallel-group trial. Clin Ther 2007;29(6):1000-1012.
25. Daniels SE, Upmalis D, Okamoto A, Lange C, Haeussler J. A randomized, double-blind, phase III study comparing multiple doses of tapentadol IR, oxycodone IR, and placebo for postoperative (bunionectomy) pain. Curr Med Res Opin 2009;25(3):765-776.
26. Gimbel J, Ahdieh H. The efficacy and safety of oral immediate-release oxymorphone for postsurgical pain. Anesth Analg 2004;99(5):1472-1477; table of contents.
27. Portenoy RK, Messina J, Xie F, Peppin J. Fentanyl buccal tablet (FBT) for relief of breakthrough pain in opioid-treated patients with chronic low back pain: A randomized, placebo-controlled study. Curr Med Res Opin 2007;23(1):223-233.
28. Daniels SE, Spivey RJ, Singla S, Golf M, Clark FJ. Efficacy and safety of oxycodone HCl/niacin tablets for the treatment of moderate-to-severe postoperative pain following bunionectomy surgery. Curr Med Res Opin 2011;27(3):593-603.
29. Katz N, Hale M, Morris D, Stauffer J. Morphine sulfate and naltrexone hydrochloride extended release capsules in patients with chronic osteoarthritis pain. Postgrad Med 2010;122(4):112-128.
30. Friedmann N, Klutzaritz V, Webster L. Efficacy and safety of an extended-release oxycodone (Remoxy) formulation in patients with moderate to severe osteoarthritic pain. J Opioid Manag 2011;7(3):193-202.
31. Ashburn MA, Slevin KA, Messina J, Xie F. The efficacy and safety of fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic pain. Anesth Analg 2011;112(3):693-702.
32. Beaulieu AD, Peloso P, Bensen W, etal. A randomized, double-blind, 8-week crossover study of once-daily controlled-release tramadol versus immediate-release tramadol taken as needed for chronic noncancer pain. Clin Ther 2007;29(1):49-60.
33. Curkovic B, Bernik N. Three-week open multi-centre study of sustained-release tramadol in various pain conditions. Arzneimittelforschung 2003;53(7):503-506.
34. Daniels S, Casson E, Stegmann JU, etal. A randomized, double-blind, placebo-controlled phase 3 study of the relative efficacy and tolerability of tapentadol IR and oxycodone IR for acute pain. Curr Med Res Opin 2009;25(6):1551-1561.
35. Hale M, Tudor IC, Khanna S, Thipphawong J. Efficacy and tolerability of once-daily OROS hydromorphone and twice-daily extended-release oxycodone in patients with chronic, moderate to severe osteoarthritis pain: Results of a 6-week, randomized, open-label, noninferiority analysis. Clin Ther 2007;29(5):874-888.
36. Hale ME, Dvergsten C, Gimbel J. Efficacy and safety of oxymorphone extended release in chronic low back pain: Results of a randomized, double-blind, placebo- and active-controlled phase III study. J Pain 2005;6(1):21-28.
37. Hale ME, Fleischmann R, Salzman R, etal. Efficacy and safety of controlled-release versus immediate-release oxycodone: Randomized, double-blind evaluation in patients with chronic back pain. Clin J Pain 1999;15(3):179-183.
38. Hogger P, Rohdewald P. Comparison of tilidine/naloxone, tramadol and bromfenac in experimental pain: A double-blind randomized crossover study in healthy human volunteers. Int J Clin Pharmacol Ther 1999;37(8):377-385.
39. Immer FF, Immer-Bansi AS, Trachsel N, etal. Pain treatment with a COX-2 inhibitor after coronary artery bypass operation: A randomized trial. Ann Thorac Surg 2003;75(2):490-495.
40. Kogan A, Medalion B, Raanani E, etal. Early oral analgesia after fast-track cardiac anesthesia. Can J Anaesth 2007;54(4):254-261.
41. McDonnell NJ, Paech MJ, Browning RM, Nathan EA. A randomised comparison of regular oral oxycodone and intrathecal morphine for post-caesarean analgesia. Int J Obstet Anesth 2010;19(1):16-23.
42. Richards P, Riff D, Kelen R, Stern W. Analgesic and adverse effects of a fixed-ratio morphine-oxycodone combination (MoxDuo) in the treatment of postoperative pain. J Opioid Manag 2011;7(3):217-228.
43. Salzman RT, Roberts MS, Wild J, etal. Can a controlled-release oral dose form of oxycodone be used as readily as an immediate-release form for the purpose of titrating to stable pain control? J Pain Symptom Manage 1999;18(4):271-279.
44. Stegmann JU, Weber H, Steup A, etal. The efficacy and tolerability of multiple-dose tapentadol immediate release for the relief of acute pain following orthopedic (bunionectomy) surgery. Curr Med Res Opin 2008;24(11):3185-3196.
45. Sunshine A, Olson NZ, Colon A, etal. Analgesic efficacy of controlled-release oxycodone in postoperative pain. J Clin Pharmacol 1996;36(7):595-603.
46. Wilsey BL, Fishman S, Li CS, Storment J, Albanese A. Markers of abuse liability of short- vs long-acting opioids in chronic pain patients: A randomized cross-over trial. Pharmacol Biochem Behav 2009;94(1):98-107.
47. Yaddanapudi LN, Wig J, Singh B, Tewari MK. Comparison of efficacy and side effects of epidural tramadol and morphine in patients undergoing laminectomy: A repeated dose study. Neurol India 2000;48(4):398-400.
48. Adams EH, Chwiecko P, Ace-Wagoner Y, etal. A study of AVINZA (morphine sulfate extended-release capsules) for chronic moderate-to-severe noncancer pain conducted under real-world treatment conditions-the ACCPT Study. Pain Pract 2006;6(4):254-264.
49. Afilalo M, Etropolski MS, Kuperwasser B, etal. Efficacy and safety of Tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: A randomized, double-blind, placebo- and active-controlled phase III study. Clin Drug Investig 2010;30(8):489-505.
50. Babul N, Noveck R, Chipman H, etal. Efficacy and safety of extended-release, once-daily tramadol in chronic pain: A randomized 12-week clinical trial in osteoarthritis of the knee. J Pain Symptom Manage 2004;28(1):59-71.
51. Florete OG, Xiang J, Vorsanger GJ. Effects of extended-release tramadol on pain-related sleep parameters in patients with osteoarthritis. Expert Opin Pharmacother 2008;9(11):1817-1827.
52. Johnson FK, Stark JG, Bieberdorf FA, Stauffer J. Relative oral bioavailability of morphine and naltrexone derived from crushed morphine sulfate and naltrexone hydrochloride extended-release capsules versus intact product and versus naltrexone solution: A single-dose, randomized-sequence, open-label, three-way crossover trial in healthy volunteers. Clin Ther 2010;32(6):1149-1164.
53. Katz N, Sun S, Johnson F, Stauffer J. ALO-01 (morphine sulfate and naltrexone hydrochloride) extended-release capsules in the treatment of chronic pain of osteoarthritis of the hip or knee: Pharmacokinetics, efficacy, and safety. J Pain 2010;11(4):303-311.
54. Korkmazsky M, Ghandehari J, Sanchez A, Lin HM, Pappagallo M. Feasibility study of rapid opioid rotation and titration. Pain Physician 2011;14(1):71-82.
55. Likar R, Schafer M, Paulak F, etal. Intraarticular morphine analgesia in chronic pain patients with osteoarthritis. Anesth Analg 1997;84(6):1313-1317.
56. Malonne H, Coffiner M, Fontaine D, etal. Long-term tolerability of tramadol LP, a new once-daily formulation, in patients with osteoarthritis or low back pain. J Clin Pharm Ther 2005;30(2):113-120.
57. Rauck RL, Bookbinder SA, Bunker TR, etal. A randomized, open-label, multicenter trial comparing once-a-day AVINZA (morphine sulfate extended-release capsules) versus twice-a-day OxyContin (oxycodone hydrochloride controlled-release tablets) for the treatment of chronic, moderate to severe low back pain: Improved physical functioning in the ACTION trial. J Opioid Manag 2007;3(1):35-43.
58. Rauck RL, Bookbinder SA, Bunker TR, etal. A randomized, open-label study of once-a-day AVINZA (morphine sulfate extended-release capsules) versus twice-a-day OxyContin (oxycodone hydrochloride controlled-release tablets) for chronic low back pain: The extension phase of the ACTION trial. J Opioid Manag 2006;2(6):325-328, 31-3.
59. Rauck RL, Bookbinder SA, Bunker TR, etal. The ACTION study: A randomized, open-label, multicenter trial comparing once-a-day extended-release morphine sulfate capsules (AVINZA) to twice-a-day controlled-release oxycodone hydrochloride tablets (OxyContin) for the treatment of chronic, moderate to severe low back pain. J Opioid Manag 2006;2(3):155-166.
60. Rosenthal M, Moore P, Groves E, etal. Sleep improves when patients with chronic OA pain are managed with morning dosing of once a day extended-release morphine sulfate (AVINZA): Findings from a pilot study. J Opioid Manag 2007;3(3):145-154.
61. Stauffer J, Setnik B, Sokolowska M, etal. Subjective effects and safety of whole and tampered morphine sulfate and naltrexone hydrochloride (ALO-01) extended-release capsules versus morphine solution and placebo in experienced non-dependent opioid users: A randomized, double-blind, placebo-controlled, crossover study. Clin Drug Investig 2009;29(12):777-790.
62. Wallace M, Rauck RL, Moulin D, etal. Once-daily OROS hydromorphone for the management of chronic nonmalignant pain: A dose-conversion and titration study. Int J Clin Pract 2007;61(10):1671-1676.
63. Webster LR, Brewer R, Wang C, etal. Long-term safety and efficacy of morphine sulfate and naltrexone hydrochloride extended release capsules, a novel formulation containing morphine and sequestered naltrexone, in patients with chronic, moderate to severe pain. J Pain Symptom Manage 2010;40(5):734-746.
64. Webster LR, Johnson FK, Stauffer J, Setnik B, Ciric S. Impact of intravenous naltrexone on intravenous morphine-induced high, drug liking, and euphoric effects in experienced, nondependent male opioid users. Drugs R D 2011;11(3):259-275.
65. Wild JE, Grond S, Kuperwasser B, etal. Long-term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis pain. Pain Pract 2010;10(5):416-427.
66. Wilder-Smith CH, Hill L, Spargo K, Kalla A. Treatment of severe pain from osteoarthritis with slow-release tramadol or dihydrocodeine in combination with NSAID's: A randomised study comparing analgesia, antinociception and gastrointestinal effects. Pain 2001;91(1-2):23-31.
67. Rothwell MP, Pearson D, Hunter JD, etal. Oral oxycodone offers equivalent analgesia to intravenous patient-controlled analgesia after total hip replacement: A randomized, single-centre, non-blinded, non-inferiority study. Br J Anaesth 2011;106(6):865-872.
68. McIlwain H, Ahdieh H. Safety, tolerability, and effectiveness of oxymorphone extended release for moderate to severe osteoarthritis pain: A one-year study. Am J Ther 2005;12(2):106-112.
69. Nicholson B, Ross E, Sasaki J, Weil A. Randomized trial comparing polymer-coated extended-release morphine sulfate to controlled-release oxycodone HCl in moderate to severe nonmalignant pain. Curr Med Res Opin 2006;22(8):1503-1514.
70. Nicholson B, Ross E, Weil A, Sasaki J, Sacks G. Treatment of chronic moderate-to-severe non-malignant pain with polymer-coated extended-release morphine sulfate capsules. Curr Med Res Opin 2006;22(3):539-550.
71. Panjabi SS, Panjabi RS, Shepherd MD, etal. Extended-release, once-daily morphine (Avinza) for the treatment of chronic nonmalignant pain: Effect on pain, depressive symptoms, and cognition. Pain Med 2008;9(8):985-993.
72. Pascual ML, Fleming RR, Gana TJ, Vorsanger GJ. Open-label study of the safety and effectiveness of long-term therapy with extended-release tramadol in the management of chronic nonmalignant pain. Curr Med Res Opin 2007;23(10):2531-2542.
73. Friedmann N, Klutzaritz V, Webster L. Long-term safety of Remoxy(R) (extended-release oxycodone) in patients with moderate to severe chronic osteoarthritis or low back pain. Pain Med 2011;12(5):755-760.
74. Braden JB, Russo J, Fan MY, etal. Emergency department visits among recipients of chronic opioid therapy. Arch Intern Med 2010;170(16):1425-1432.
75. Gallagher RM, Welz-Bosna M, Gammaitoni A. Assessment of dosing frequency of sustained-release opioid preparations in patients with chronic nonmalignant pain. Pain Med 2007;8(1):71-74.
76. Kosinski MR, Schein JR, Vallow SM, etal. An observational study of health-related quality of life and pain outcomes in chronic low back pain patients treated with fentanyl transdermal system. Curr Med Res Opin 2005;21(6):849-862.
77. Rauck RL, Bookbinder S, Bunker T, etal. Oral once-a-day AVINZA (morphine sulfate extended release capsules) vs. twice daily OxyContin (oxycodone hydrochloride controlled-release) for the treatment of chronic moderate to severe low back pain; final (part I and part II) study results 84 3102. J Pain 2006;4(7):S57.
78. Rauck RL, Podolsky G, Galer B, etal. Randomized, double-blind, placebo-controlled 12-week study assessing the efficacy of oxymorphone extended release in opioid-naïve patients with chronic low back pain 83 3101. J Pain 2006;5(7):S55.
79. Rauck RL, Bookbinder S, Bunker T, etal. Oral once-a-day AVINZA (morphine sulfate extended release capsules) vs. twice daily OxyContin (oxycodone hydrochloride controlled-release): A randomized, multi-centre study for the treatment of chronic moderate to severe low back pain 82 3100. J Pain 2006;3(7):S54.
80. Raber M, Hofmann S, Junge K, etal. Analgesic efficacy and tolerability of tramadol 100mg sustained-release capsules in patients with moderate to severe chronic low back pain. Clin Drug Investig 1999;17:415-423.
81. Sorge J, Sandler T. Comparison of the analgesic efficacy and tolerability of tramadol 100mg sustained-release tablets and tramadol 50mg capsules for the treatment of chronic low back pain. Clin Drug Investig 1997;14:157-164.
82. Kalso E, Edwards JE, Moore RA, McQuay HJ. Opioids in chronic non-cancer pain: Systematic review of efficacy and safety. Pain 2004;112(3):372-380.